학술논문
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
Document Type
Article
Author
Source
In eClinicalMedicine December 2022 54
Subject
Language
ISSN
2589-5370